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ABSTRACT
There have been great advances in ventricular assist device (VAD) treatment for pediatric 
patients with advanced heart failure. VAD support provides more time for the patient in the 
heart transplant waiting list. Augmented cardiac output improves heart failure symptoms, 
end-organ function, and general condition, and consequently provides beneficial effects on 
post-transplant outcomes. Miniaturized continuous flow devices are more widely adopted for 
pediatric patient with promising results. For infants and small children, still paracorporeal 
pulsatile device is the only option for long-term support. Younger age, congenital heart 
disease, biventricular support, patient's status and end-organ dysfunction at the time of 
implantation are risks for poor outcomes. Patient selection, timing of implantation, and 
selection of device for each patient are critical for optimal clinical outcomes.
Keywords: Heart failure; Pediatric; Ventricular assist device; Extracorporeal membranous 
oxygenation; Cardiac transplantation
INTRODUCTION
Advances in mechanical circulatory support have changed the management strategy of 
the advanced heart failure. Heart transplantation had been the only solution for end-stage 
heart failure refractory to medical management. With the technological development, more 
durable and smaller ventricular assist devices (VADs) with less complication became available 
and accumulation of clinical experience made improvement in care of patients on mechanical 
circulatory support. Durable implantable VAD has become a standard mode of care for 
advanced heart failure. In the current era, 30–50% of patients listed for heart transplant 
utilize a bridge to transplant strategy. VAD is also adopted as a mode of long-term destination 
therapy (DT) for end-stage heart failure.
Like adults, number of pediatric patients with advanced heart failure is increasing.1) The 
evolution of surgical repair and medical management in congenital heart disease and the 
availability of cardiac transplantation as a treatment option in end-stage heart disease have 
increased the need for mechanical cardiopulmonary support in pediatric patients. In many 
countries, children and infants listed for heart translation tend to have longer waiting time 
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Pediatric Ventricular Assist Device
than adults, and significant portion of the patients die due to progression of the heart failure 
while awaiting a suitable donor heart. Mechanical circulatory support can improve survival 
to transplant by allowing critically ill patients to be bridged to transplantation. Despite 
widely available advanced implantable VADs in adults, devices for small patients are still 
very limited. In the absence of appropriate sized VADs for pediatric patients, extracorporeal 
membrane oxygenation (ECMO) has been most widely used mechanical circulatory support 
for pediatric patients. Although ECMO has advantages such as easy availability, quick 
initiation of support, low cost and providing oxygenation, it has limitations including 
limited durability, incomplete decompression of the failing ventricle and relatively high-
risk of complications. In a prospective clinical trial of a pediatric VAD in the United States, 
compared to the propensity-score–matched historical control groups who were undergoing 
ECMO, survival rates were significantly higher with the VAD support group.2) Definitely 
ECMO has its role in selected patients, but selection of appropriate mechanical circulatory 
support are critical for optimize patient's outcomes.
PATIENT SELECTION
The etiology of advanced heart failure in pediatric patient include diverse disease such as 
acute myocarditis, cardiomyopathy, and various forms of congenial heart disease.3) Patient 
selection and timing of VAD implantation is important to successful outcome. End-organ 
dysfunctions such as acute and chronic kidney, liver, pulmonary disease are common 
complications of end-stage heart failure. Early intervention became the rule in adult heart 
failure to prevent irreversible end-organ damage and optimize patient outcome.4) Experience 
of VAD in pediatric patients is are still limited compared to those of adult counterparts. 
However, the Berlin EXCOR® USA trial clearly demonstrated that degree of hepatic or renal 
dysfunction as well as Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) profile at the time of VAD implantation are major risk factors for mortality.5) 
Clinical review of German Heart Institute's 23-year experience also demonstrated earlier 
implantation yielded better results.6) However, it should be considered that still mechanical 
circulatory support is not risk-free treatment. To identify the optimal timing, there should be 
balance between the device related complication risks (thrombosis, anticoagulation related 
problems, infection, etc.) and the risks of progression of end-organ dysfunction.
Evaluation of need for mechanical circulatory support should begin in any patients requiring 
inotropes and/or showing signs of worsening heart failure with early evidence of end-
organ dysfunction despite medical treatment. An increase in serum blood urea nitrogen, 
creatinine, hepatic enzymes, worsening pulmonary edema, rising serum lactate, and 
decrease in mixed venous oxygen saturation are indicators of worsening cardiac output.7) 
Presence or progression of end-organ dysfunction (e.g., neurologic: altered mental status; 
respiratory: intubated; gastrointestinal: inability to tolerate enteral feeds; serum markers 
for renal and hepatic function; musculoskeletal: inability to ambulate) should be thoroughly 
evaluated and monitored.
Hetzer et al.6) reported that criteria for VAD implantation have been modified and changed 
towards earlier implantation. Their current indications are 1) low cardiac output associated 
with metabolic acidosis; 2) rapid deterioration of the circulation with cardiac index 
<2.0 L/min/m2 with inotrope dependence, especially on epinephrine; 3) mixed venous 
saturation <40%; 4) oliguria (<1 mL/kg/min); 5) critical peripheral perfusion; and 6) 
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echocardiographically confirmed massive impairment of cardiac function despite maximal 
pharmacological treatment, signs of early renal hepatic and respiratory failure and high or 
progressive increase in B-type natriuretic peptide (BNP) or N-terminal proBNP level.
The contraindications to mechanical circulatory support in pediatric patients are similar 
to those in adults. When the indication for a VAD is as a bridge to transplantation, any 
contraindication to transplant constitutes a contraindication to use of mechanical support. 
Generally, active systemic infection, extreme prematurity, very body weight (<2.0 kg), 
severe significant neurologic damage, a constellation of congenital anomalies with poor 
prognosis, and chromosomal aberrations are considered contraindications for mechanical 
circulatory support.8)9) Multisystem organ failure is a relative contraindication, however 
special consideration needs to be given as hemodynamic improvement may reverse end-
organ dysfunction in some cases. Both hepatic and renal dysfunction have been shown 
to improve with VAD related improved hemodynamics.10) Likewise, among the described 
contraindications, several of these are relative contraindications and need to be evaluated on 
an individual patient basis.
Pulmonary hypertension and elevated pulmonary vascular resistance are commonly 
encountered complication of chronic heart failure. VAD support may improve pulmonary 
hypertension by unloading the left ventricle (LV) and decreasing the left atrial pressures.11-13) 
The presence of irreversible pulmonary hypertension is considered a contraindication for VAD 
support, but still patients should be evaluated for candidate for biventricular support rather 
than left ventricular support alone before preclude from the mechanical circulatory support.
Neuromuscular disease has generally been considered a contraindication to mechanical 
circulatory support. However, there has been change in some specific diseases. Duchenne 
muscular dystrophy (DMD) is an X-linked recessive disorder, characterized by progressive 
skeletal muscle weakness, loss of ambulation, and death secondary to cardiac or respiratory 
failure. Improvements in general management and respiratory support, heart failure is a 
frequent finding in this patient population, and major cause morbidity and mortality, but 
they are rarely candidates for cardiac transplantation. The use of VADs as a DT in DMD 
patients has been described.14)15) The benefit of VAD treatment for this patient group is still 
unclear and must be studied.
SPECIAL CONSIDERATIONS
Special consideration should be given to small infants and patients with congenital heart 
disease (CHD) because of limited device options and a higher morbidity profile for these 
patients. In the congenital heart disease population, several anatomic issues and complex 
physiologic features make it difficult to implant an assist device. In the presence of intra-
cardiac shunt, regulation of pump flow and balancing the patient's systemic and pulmonary 
circulation under VAD support is very difficult. In short-term support, such patients can be 
treated with ECMO. For long-term support with VADs, Intracardiac shunt or extracardiac 
systemic-to-pulmonary shunt including a patent ductus arteriosus, aortopulmonary window 
or surgically created shunt needs to be ligated or closed prior to implantation of device.
Circulatory support using VAD is more challenging for patients with univentricular physiology. 
There was successful use of Berlin Heart EXCOR® for 7 weeks until heart transplantation 
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in a 15-month-old patient with single ventricle and systemic to pulmonary artery shunt 
physiology.16) Another case report described a successful bridge to transplant a 14-month-old 
patient.17) Despite these cases, overall the support option for failing shunted single ventricle 
patients are limited and the outcomes are poor. For patients with Glenn physiology, there 
have been reported cases of successful use VAD for ventricular dysfunction.18)19) Although the 
evidence is limited and success has been inconsistent, systemic VAD support with a continuous 
flow device appears to be feasible and may provide an effective support.20)
Surgical outcome and long-term survival after Fontan operation had dramatic improvement, 
however a significant portion of patients will experience Fontan circulatory failure. In 
patients with failing Fontan circulation, there have been several reports describing successful 
application of for systemic VAD using pulsatile device21)22) and implantable continuous 
flow VADs.23-25) For this group of patients, continuous-flow (CF)-VAD is regarded superior 
to the pulsatile VADs.24) In Fontan physiology, there is no subpulmonary ventricle and 
pulmonary circulation depends on passive flow via cavopulmonary connections. Pulsatile 
device decompresses the systemic ventricle only during the diastolic phase of the pump. The 
pulmonary circulation might be more efficient with continuous decompression with CF-
VADs than intermittent decompression with pulsatile VADs. There are multiple reasons for 
Fontan circulatory failure such as systemic ventricular systolic and/or diastolic dysfunction, 
elevated pulmonary vascular resistance, associated lymphatic abnormalities (chylothorax, 
protein losing enteropathy, and plastic bronchitis).26) Systemic VAD support will be effective 
for those who has features of ventricular failure. A case of successful long-term isolated RVAD 
was also has been reported. A patient with severe right side circulatory failure with preserved 
ventricular function after Fontan conversion could be successfully bridged with right side 
VAD support with a Berlin Heart EXCOR®.27) If Fontan failure is due to other hemodynamic 
reasons rather than systemic ventricular dysfunction, biventricular support or implantation 
of total artificial heart (TAH) can be options,28)29) although experience is still limited. 
Indication, timing, mode of support and device selection should be further refined.
Prior to VAD implantation, all patients should be evaluated for valvar insufficiency. 
Competence of the native aortic valve is important in left ventricular assist device (LVAD) 
setting. Aortic valvar regurgitant flow can make the device ineffective for hemodynamic 
support. Aortic valve regurgitation should be addressed prior to implantation of the device. 
In patients with severe aortic regurgitation with structural abnormality, aortic valve needs 
to be replaced or closed. For mild to moderate aortic regurgitation simple coaptation stitch 
at the central portion of the aortic cusps can effectively eliminate the regurgitation.30) In 
patients with mitral insufficiency, the severity of mitral insufficiency often improves after 
device implantation. However, in others, the valve may need to be repaired at the time of 
device implantation, especially for pulsatile VADs.
Another issue that requires special considerations is the small or severely hypertrophic 
systemic ventricle cavity. In patients with restrictive or hypertrophic cardiomyopathy, the 
systemic ventricle cavity is small and the standard left ventricular apical cannulation has a 
significant risk of inflow cannula occlusion. Inflow cannula can be placed in the left atrium 
for pulsatile VADs. Initial use of Berlin Heart EXCOR® was with the left atrial cannula, but 
LV apical cannula is superior in clinical outcome.31) If atrial cannulation is not feasible or 
for continuous flow devices, aggressive left ventricular myectomy32) and more aggressively 
resection of papillary muscle of the mitral valve with mitral valve replacement technique33) 
can be used to avoid inflow obstruction.
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DEVICE SELECTION
The etiology of advanced heart failure in pediatric patient include diverse disease such as 
acute myocarditis, cardiomyopathy, and various forms of congenial heart disease.3) The 
etiologies of heart failure are important to choose the optimal mechanical support devices 
and mode support.8)34) Diverse patient's physique is another critical feature of pediatric 
patients. Patients can present at any time from infancy to adolescent, and these size 
differences have important implications for support options.
Once a patient is determined to be a candidate for mechanical circulatory support, options 
of device include ECMO, temporary VAD, or durable VADs.8)35) In acute settings (cardiac 
arrest or acute refractory cardiac failure), ECMO is often the first choice because of its rapid 
availability. It may be delivered by percutaneous venous and arterial cannulation through the 
neck or femoral vessels. ECMO may be beneficial when there is hypotension despite inotropes, 
respiratory failure, severe coagulopathy or hepatic dysfunction. However, ECMO support 
should remain limited to patient with cardiorespiratory failure. The presence of the oxygenator 
in the ECMO circuit increase the inflammatory response and thereby increase the need for 
higher anticoagulation level compared to temporary VAD circuit. After a few days of ECMO 
support, if the patient's pulmonary function is adequate, switch over the ECMO to VAD should 
be considered to avoid ECMO related complications such as coagulation disorders or infection. 
Based on the etiology of the disease, short-term or long-term devices are chosen.
Once decision is made to proceed with VAD placement, the next step is to determine if only 
LVAD is required or if the right heart also need right VAD support. And the device should 
be chosen based on the anticipated duration of support, the destination of MCS and the 
availability of devices.
For acute and potentially reversible diseases patients can be supported with temporary VAD. 
Potential advantages over ECMO are owing to the avoidance of an oxygenator and better 
unloading of a failing ventricle. Short-term devices are usually used for acute process such 
as myocarditis, postcardiotomy ventricular dysfunction, or acute cardiac graft rejection 
with a hope to cardiac recovery and subsequent VAD explant.35) The purpose is to support a 
patient with acute decompensated heart failure until the patient recovers sufficient cardiac 
function or until further long-term therapy is indicated based on recovery of end-organ 
function. Generally, length of support is limited to 2 weeks. Centrifugal flow pumps are most 
commonly used for temporary ventricular assist. Commonly used pumps include Rotaflow® 
(MAQUET Cardiovascular, Wayne, NJ, USA) and CentriMag® (Thoratec Corp., Pleasanton, 
CA, USA). These pumps require central cannulation and can be used in children of all sizes 
from neonates to adolescents.
Percutaneous temporary VAD devices are developed and used. These devices can be 
placed without sternotomy. Tandem Heart (Cardiac Assist Inc., Pittsburgh, PA, USA) is 
an extracorporeal centrifugal pump with percutaneously placed inflow cannula in the left 
atrium across the inter-atrial septum and an outflow cannula in the femoral artery. Impella® 
(Abiomed, Danvers, MA, USA) is another type of recently used percutaneous device. It is 
inserted through the femoral artery and placed in the LV across the aortic valve, it enables 
continuous blood flow up to 5.0 L/min. These percutaneous devices offer the ability to 
augment the cardiac output and left heart decompression with a less invasive approach. This 
can be a valuable operation in the setting of redo-sternotomy or complex anatomy for central 
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cannulation. However, it cannot be applied for small children and experience in pediatric 
patients are still very limited.
Short-term devices are also used for bridge to decision purpose. When a patient present with 
refractory heart failure and the etiology or candidacy for transplantation due to end-organ 
dysfunction is not clear. For a period of support with short-term devices, these patients may be 
considered to a long-term VAD if they are indeed candidate for recovery or heart transplant.
In the chronic disease process, implantation of durable VADs provides numerous benefits. 
The patients can be extubated, fed normally and start exercise or walking to regain physical 
strength. Presently, more than 95% of the VAD implanted in adults are intracorporeal 
continuous flow devices.36) The blood pumping mechanism of VAD has changed from 
pulsatile pumps to continuous flow pump using axial flow or centrifugal flow technology. 
Much smaller size and less energy consuming feature made it possible to be intracorporeally 
implanted. Magnetically or hydrodynamically levitating technology pump structure further 
decrease the risk of thrombosis. continuous flow LVAD is superior to pulsatile devices 
in stroke and device failure.34) Progressively miniaturization of devices has allowed for 
implantation of this device for children. The earliest reports of durable VAD use in children 
were rare and largely limited to the off label use of adult sized pulsatile VADs or short-term 
smaller, pulsatile pumps.
The HeartMate II (St. Jude Medical, St. Paul, MN, USA) is a Food and Drug Administration 
(FDA) approved 2nd generation implantable device with axial-flow technology. HeartMate II 
is approved for bridge to transplant and DT by FDA in the USA, and is the most widely used 
device in adults with over 20,000 implants worldwide.37) It can be used in adolescent patients 
probably down to a body surface area (BSA) 1.2 m2. The HVAD (HeartWare Inc., Framingham, 
MA, USA), is a 3rd generation continuous flow VAD with a centrifugal pump. It is even smaller 
than HeartMate II and is implanted in pericardial space. Owing to Its compact size, the HVAD 
has been widely adopted in the pediatric patients. It can be used in small patients down to BSA 
0.7 m2.38)39) Analyzing the outcome of 205 pediatric patients demonstrated satisfactory results; 
a 1-year mortality rate was 10% and the other patients received heart transplantation, explanted 
for recovery or remained on device support.40) Thoratec Company also released a 3rd generation 
centrifugal pump (HeartMate 3) which is designed to be placed in the pericardial space. Like 
HVAD, this device may be a good option for pediatric use due to its relatively compact design.
Miniaturized continuous flow devices for infants and children has been developed and some 
of them got FDA approval for clinical trial. Until now, only device suitable for infants or 
small children are pulsatile pumps. The Berlin Heart EXCOR® (Berlin Heart GmbH, Berlin, 
Germany) is a pulsatile pneumatically driven paracorporeal VAD. It is the most commonly 
used pediatric VAD throughout the world and only long-term FDA approved VAD available 
for neonates and infants in the United States. The variety of pump sizes (10, 15, 25, 30, 50, 
60, and 80 mL stroke volume) made it possible to support children ranging from neonates 
to adulthood. In patients for whom the stroke volume of the pump is insufficient, the pump 
is easily replaced either in the operation theater or at the bedside.6) Multiple studies have 
demonstrated the benefit of VAD support on mortality and overall condition at transplant.2)5)
For patients with multiple valvar disease, multiple residual abnormalities that requires 
surgical correction prior to VAD implantation, or complex anatomy for implantation of VADs, 
TAH is an option.28) Currently, SynCardia TAH (SynCardia Systems Inc., Tucson, AZ, USA) is 
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the only approved available TAH. It is an implantable biventricular device that anatomically 
replace both ventricles. Patient can be discharged from the hospital with a portable driving 
unit (Freedom® Portable Driver). Successful bridge to transplantation rate is up to 79%.41) 
Children with rejection post heart transplant also can benefit from TAH implant, as 
immunosuppression can be discontinued. Large size of the device limits this device to be 
used only for patients with big body physique. Now the company manufactures a smaller 50 
cc pump to fit patients of smaller stature, allowing more women and adolescents to access 
this device, although still cannot be used for small children.
PATHOPHYSIOLOGIC AND CLINICAL CHANGES AFTER 
VENTRICULAR ASSIST DEVICE SUPPORT
Initiation of LVAD support results in significant physiologic and hemodynamic changes. 
LVAD support unloads the left ventricle throughout the cardiac cycle and this LV unloading 
reduces LV end-diastolic volume and pressure (Figure 1). And reduction of the left atrial 
pressure and pulmonary arterial pressure follows.42) Reduction of LV end-diastolic pressure 
also improves the coronary perfusion pressure and improves coronary circulation. In case of 
CF devices, the forward flow during the diastole improves coronary perfusion.
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A B C
D E F
Figure 1. Chest X-ray (A-C) and echocardiogrphic finding (D-F) before and after LVAD support. (A, D) pre-LVAD support, (B, E) post-LVAD support 2 weeks, 
(C, F) post-implantation 5 months. Serial chest-ray demonstrates the progressive decreased heart size and pulmonary congestion. On pre-LVAD support 
echocardiography, left ventricle was dilated and interventricular septum was deviated to the right. After LVAD support, left ventricle is unloaded and 
interventricular septum is in neutral position. 
LVAD = left ventricular assist device.
The unloading of the LV reduces the wall stress and as a consequence decreases the metabolic 
demand of the left ventricular myocardium. Changes in right ventricular (RV) afterload also 
reduces the workload and metabolic demand of the right ventricle. Over a period of time, 
these changes result in positive remodeling of the left and right ventricle that allows the 
recovery of the myocardium in some cases. Some of the mechanisms related to the post-LVAD 
support recovery of ventricular myocardium are related to the molecular changes, reduction 
in cardiomyocyte hypertrophy, interruption or changes to the apoptotic pathway, changes in 
calcium handling, improved excitation-contraction coupling and changes to the extracellular 
matrix.43) These mechanisms need to be further investigated to reveal the process of 
myocardial recovery and to provide a more chance of recovery for the patients.
Augmented cardiac output by LVAD support improves end-organ function. The most 
immediate response occurs in the respiratory system; improvement in the respiratory 
compliance leads to improved symptoms. Stabilization of RV function also allows rapid 
weaning off respiratory support and oxygen. Enhanced cardiac output and systemic organ 
perfusion leads to renal and hepatic functional improvements. A majority of patients have 
pre-implantation cardiorenal syndrome and this improves significantly after initiation of LVAD 
support.44-46) Similarly, patients with pre-implantation hepatic dysfunction experience hepatic 
recovery. Preoperative total bilirubin, postoperative bilirubin and central venous pressure (CVP) 
were predictors of recovery or non-recovery of liver dysfunction.47) Most pediatric patients with 
chronic heart failure suffer from poor nutritional status. Restoration of cardiac output and 
mesenteric perfusion allows for enteral feeding and nutritional rehabilitation.
Preservation and restoration of end-organ function under VAD support allows to wean from 
ventilator and extubate, mobilize, feed and rehabilitate the patient. Improved patient's 
condition waiting for heart transplantation improves the post-transplantation survival.48)49) 
Compared to bridging to heart transplant with ECMO, post-transplantation course bridged 
with VAD was notably better.50) VAD is effective in improving patient's clinical condition, 
survival and post-transplantation course.
RV failure
Usually, LVAD support gives beneficial effects on RV function. This is mainly related to the 
reduction of the RV afterload. Decreased LV end-diastolic pressure, left atrial pressure, and 
pulmonary capillary wedge pressure lowers the pulmonary arterial pressure. However, acute 
change in ventricular geometry may cause deleterious effect on RV systolic function. The 
synchronous movement of the interventricular septum during systole contributes 40% to the 
overall output from the RV. LV unloading with the LVAD support results in displacement of the 
interventricular septum towards the LV. This results in loss of septal contribution to the RV 
systolic function and RV output. This effect is aggravated when LV is too aggressively unloaded. 
Also augmented cardiac output by LVAD support significantly increase the RV preload.
In addition to cardiac geometric and RV preload changes, underlying pathology, such as 
cardiomyopathy or pulmonary hypertension, may contribute to RV failure. Although PA 
pressure is expected to decrease after LVAD support, chronically elevated PA pressure and 
elevated pulmonary vascular resistance may not decrease immediately. Cardiac surgery 
and cardiopulmonary bypass related lung injury can also elevate the pulmonary vascular 
resistance postoperatively. RV failure after LVAD implantation is noted in 40–60% of pediatric 
patients and in 20–25% of adults.51)52) The RV failure is a significant independent risk factor 
for morbidity and mortality and should be thoroughly assessed and managed.
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For patients with post-LVAD RV failure, optimization of VAD setting may help to restore RV 
function. By reducing the LV drainage to restore the adequate LV volume, the interventricular 
septum can achieve a midline position. This should be balanced with adequate systemic 
cardiac output and perfusion. Reduction in the systemic cardiac output is usually well 
compensated by improvement in the RV output and increase in the left heart preload. Over 
displacement of interventricular septum towards the left ventricle can also contribute 
the tricuspid valve regurgitation. Optimizing LVAD setting and interventricular septal 
configuration can improve the tricuspid regurgitation.
Management of volume status is also important in the setting of RV dysfunction and 
dilatation after LVAD implantation. Echocardiography is helpful to assess RV systolic 
function and its relationship with the interventricular septal configuration. Hemodynamic 
monitoring such as CVP and pulmonary capillary wedge pressure provide more detailed 
information to understand the patient's post-LVAD implantation hemodynamic changes. A 
high CVP has been associated with hepatic dysfunction, delayed recovery, requirement for 
biventricular support and mortality. Contrarily, very low CVP reduce the left heart preload 
and left heart cardiac output. Therefore, maintenance of adequate intravascular volume 
status is crucial in the immediate postoperative period.53)
After implantation of LVAD, treatment of elevated pulmonary vascular resistance must be 
initiated early to prevent RV failure. Management should target to get optimal ventilation 
and oxygenation and management of volume overload. Inhalation of nitric oxide has 
been proven to decrease pulmonary vascular resistance. In a randomized trial of patients 
with LVAD and pulmonary hypertension, inhaled nitric oxide of 20 ppm was associated 
with significant reduction in mean pulmonary artery pressure and significant increase in 
LVAD outputs compared to nitrogen.54) This beneficial effect has also been shown in other 
series and reports.55)56) Sildenafil can be used to for patients requiring longer-term therapy 
for pulmonary hypertension.57) For patients with signs of refractory RV dysfunction such 
as elevated CVP and persistent low cardiac output, short-term or long-term right side 
mechanical support should be considered.
OUTCOMES
With the increased use of VAD in pediatric age group, many reports of single-center 
experience8)58) and device specific results5)39) has been published. These reports described 
improvement in outcomes of mechanical circulatory support for children in bridge to 
transplant or recovery purpose. In 2012, Registry for Pediatric Mechanical Assisted 
Circulatory Support (PedMACS) was launched to serve as a comprehensive registry of 
temporary and durable VADs in children and adolescents. Until the end of 2017, data on more 
than 750 devices in more than 600 patients were collected. In the latest report published in 
2019, because of data incompleteness, data of 423 patients with 508 devices at 30 hospitals 
in the United States were analyzed.59) The diagnosis was cardiomyopathy (62%), congenital 
heart disease (20%), myocarditis (11%) and others in 7% with 52 patients (12% of total 
patients and 60% of patients with CHD) in single-ventricle physiology. Forty-seven percent of 
the patients had implantable continuous flow pumps and 29% of patients had paracorporeal 
pulsatile devices and the remaining 19% were supported with paracorporeal continuous 
devices. Positive outcome (alive on device or bridge to transplantation/recovery) was achieved 
in 80% of the patient. The patient cohort for implantable continuous flow was significantly 
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different from the paracorporeal pulsatile cohort. Understandably, paracorporeal pulsatile 
cohort was younger than implantable continuous flow pump cohort (age at implant, 
3.9±5.2 vs. 13.4±3.8 years). Moreover, they are in more advanced heart failure (41% vs. 
19% in INTERMACS profile 1 and 77% vs. 12% intubated at implant). And CHD was more 
common in paracorporeal pulsatile pump cohort (21% vs. 12%). Consistent with their cohort 
composition, device type positive outcomes at 6 months were 77% in paracorporeal pulsatile 
pumps and 92% in implantable continuous flow pumps. INTERMACS profile 1, biventricular 
assist device, paracorporeal devices, small-volume institutions, low age, low weight, 
intubation and liver dysfunction at time of implant were hazards for early death.
Major adverse events were not uncommon and include infection, bleeding, neurologic events 
and device malfunction. In paracorporeal pulsatile pump, incidence of device malfunction 
and neurologic dysfunction were 33% for each, bleeding 26% and infection 26%. Implantable 
continuous flow pumps have almost same risk of bleeding and infection (28% and 30%). 
Incidence of device malfunction (19%) and neurologic dysfunction (18%) was relatively 
low, but still not negligible. Although positive outcomes can be obtained in majority of the 
patients, still patients are exposed to major complications.
CONCLUSION
There have been great advances in VAD treatment in pediatric heart failure patients. With the 
improvement in patient care, patient selection and timing of VAD implantation, as well as 
technologically advanced devices, in selected group of pediatric patients, majority of them can 
be successfully bridged to transplant or supported for recovery. However, it is still challenging 
to support infants and small children and patients with congenital heart disease. Further 
clinical and technical improvement will lead to more pediatric lives saved by VAD support.
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